A randomized, double-blind, two arm, parallel, placebo controlled study of rimonabant 20 mg effect on high density lipoprotein kinetics in patients with abdominal obesity and additional cardiometabolic risk factors.

Trial Profile

A randomized, double-blind, two arm, parallel, placebo controlled study of rimonabant 20 mg effect on high density lipoprotein kinetics in patients with abdominal obesity and additional cardiometabolic risk factors.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Dyslipidaemias; Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jan 2009 Actual patient numbers added (n=64), as reported by Clinicaltrials.gov
    • 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top